Clinical trials · Chicago, IL
Atopic Dermatitis clinical trials in Chicago
We’re tracking 14 recruiting atopic dermatitis studies with a site in or near Chicago — including Early Phase 1, Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
Chicago, IllinoisAges 6 years+ - NCT05042258RecruitingPhase 4
Dupilumab to improve sleep and itch in children with eczema
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Chicago, IllinoisAges 6–17 - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Chicago, IllinoisAges 18–63 - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Chicago, IllinoisAges 6 months–18 years - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Chicago, IllinoisAges 2–11 - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Chicago, IllinoisAges 12 years+ - NCT07050810Enrolling by invitationEarly Phase 1
Bath system for chronic skin conditions
This study tests a special bath system (Thera-Clean Microbubbles) to see if it helps people with certain skin conditions like psoriasis, eczema, epidermolysis bullosa, or ichthyosis. It's designed for people whose skin is stable and who can follow a home bathing routine.
Chicago, IllinoisAges 2 years+ - NCT07277660RecruitingPhase 2
Study of galvokimig for adults with moderate-to-severe eczema
This trial tests whether a new medication, galvokimig, can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with creams or ointments. The study will measure how well the drug works, its safety, and how it behaves in your body.
Chicago, IllinoisAges 18 years+ - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Chicago, IllinoisAges 18–75 - NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Skokie, IllinoisAges 18 years+ - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Skokie, IllinoisAges 18–65 - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Rolling Meadows, IllinoisAges 18–75 - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Rolling Meadows, IllinoisAges 18–74 - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
North Chicago, IllinoisAges 12 years+
Hear when a new Atopic Dermatitis trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Atopic Dermatitis trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting atopic dermatitis studies listed above.
- Northwestern University · 5 studies
- Inmagene Site 2 · 2 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Atd002 52017
- Atd002 52018
- DeNova Research
- Endeavor Health
- Enveda Investigative Site
What taking part in a atopic dermatitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting atopic dermatitis studies in Illinois.
Common questions
- Are there atopic dermatitis clinical trials near Chicago?
- Yes. We're currently tracking 14 recruiting atopic dermatitis studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a atopic dermatitis study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New atopic dermatitis studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.